Active	Status	Sponsor type	Region	Phase	Filter
16 Active 6 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

10 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wilmink, Hanneke
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion	Active, not recruiting	2	250	Europe, Canada, Japan, US, RoW	zenocutuzumab (MCLA-128), bispecific, MCLA-128	Merus N.V.	Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion	12/26	12/26
Guren, Tormod
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion	Active, not recruiting	2	250	Europe, Canada, Japan, US, RoW	zenocutuzumab (MCLA-128), bispecific, MCLA-128	Merus N.V.	Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion	12/26	12/26
NCT02275416: Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma From positive 5-year overall survival data in combination with UV1 for metastatic malignant melanoma Dec 2020 - Dec 2020: From positive 5-year overall survival data in combination with UV1 for metastatic malignant melanoma	Completed	1/2	12	Europe	Ipilimumab, Yervoy, UV1 vaccine, UV1, GM-CSF, Leukine	Ultimovacs ASA, Oslo University Hospital	Malignant Melanoma	10/16	11/20
Dahle, Gry
RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation	Active, not recruiting	N/A	200	Europe, RoW	Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)	Abbott Medical Devices	Mitral Valve Regurgitation	05/25	05/29
Opdam, Frans L
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion	Active, not recruiting	2	250	Europe, Canada, Japan, US, RoW	zenocutuzumab (MCLA-128), bispecific, MCLA-128	Merus N.V.	Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion	12/26	12/26
NCT03767075 / 2017-005108-89: A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)	Recruiting	2	1000	Europe	Atezolizumab, Futibatinib, TAS-120, Amivantamab, JNJ-372	Vall d'Hebron Institute of Oncology, Roche Pharma AG, Iqvia Pty Ltd, Taisho Pharmaceutical Co., Ltd., Janssen, LP	Advanced Solid Tumor	05/25	11/26
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination	Recruiting	1/2	576	Europe, US, RoW	MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy	Merus N.V.	Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer	03/26	03/27
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	Recruiting	1	400	Europe, US, RoW	KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib	Pierre Fabre Medicament	Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma	12/24	12/25
Dong-Wan, Kim
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion	Active, not recruiting	2	250	Europe, Canada, Japan, US, RoW	zenocutuzumab (MCLA-128), bispecific, MCLA-128	Merus N.V.	Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion	12/26	12/26
Smits, Minke
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion	Active, not recruiting	2	250	Europe, Canada, Japan, US, RoW	zenocutuzumab (MCLA-128), bispecific, MCLA-128	Merus N.V.	Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion	12/26	12/26